#hc-wainwright
Latest news and interesting information about hc-wainwright.
H.C. Wainwright Reaffirms Mineralys Buy
H.C. Wainwright reiterated a Buy rating on Mineralys Therapeutics with a $56 price target after positive trial data.
Summit Therapeutics downgraded to neutral
H.C. Wainwright downgrades Summit Therapeutics to Neutral due to competitive pressure from Merck.
H.C. Wainwright Raises Immunovant Target to $40
H.C. Wainwright raises Immunovant price target to $40 from $35 after positive Phase 2 RA data, maintains Buy rating.
H.C. Wainwright Reiterates Protara Buy Rating
H.C. Wainwright reiterates Buy rating on Protara Therapeutics (TARA) with $27 target. Encouraging results from lymphatic malformation and bladder cancer trials.
H.C. Wainwright reiterates MindWalk stock rating on platform validation
H.C. Wainwright reiterates Buy rating and $5 target on MindWalk stock, citing platform validation and strong pipeline. Read more.
Traws Pharma Gets $8 Price Target from H.C. Wainwright
H.C. Wainwright reaffirms Buy on Traws Pharma with $8 target. Financing secured for influenza drug trial. Read more on Bond.az.
H.C. Wainwright Upgrades Circle Stock to Buy
H.C. Wainwright upgrades Circle Internet Group stock to Buy, citing ARC token presale and Arc network potential. Price target raised to $150.
H.C. Wainwright Reiterates Immunic Stock Rating
H.C. Wainwright maintains Buy rating and $22 price target on Immunic stock. The company awaits pivotal MS drug trial results. Read more on Bond.az.
Titan Mining Price Target Cut by H.C. Wainwright
H.C. Wainwright cuts Titan Mining price target to $6.50, maintains Buy. Stock up 357% in a year, but Bond.az flags overvaluation risk.
...